Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT
Recruiting · NCT07534475 · Interventional (participants receive a specific treatment) · Lead sponsor: Medipol University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This prospective, open-label clinical trial aims to compare a novel "Venous Tourniquet with Regional Low-Dose Sugammadex" method against the gold standard "Arterial Tourniquet" (Isolated Forearm Technique - IFT) for monitoring motor seizure activity during Electroconvulsive Therapy (ECT). Using a within-subject (intra-individual) design, each of the 40 enrolled patients will receive an arterial tourniquet on one arm and a venous tourniquet on the other arm simultaneously. The study will evaluate clinical efficacy in observing motor seizures, comparing the duration and visibility between the two limbs of the same patient, as well as assessing overall patient comfort and hemodynamics.
Who can take part
Inclusion criteria
- Patients scheduled for elective Electroconvulsive Therapy (ECT).
- ASA (American Society of Anesthesiologists) physical status I to III.
Exclusion criteria
- Known neuromuscular diseases (e.g., Myasthenia Gravis).
- Known allergy or hypersensitivity to sugammadex, rocuronium, ketamine, dexmedetomidine, or propofol.
- Presence of venous insufficiency, lymphedema, or active infection in the upper extremities.
- Severe cardiovascular instability.
Where it is running
2 locations listed.
- Istanbul Medipol University - Istanbul, Turkey (Türkiye)
- Istanbul Medipol University - Istanbul, Turkey (Türkiye)